IONS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
242.7M
-9.4%
267.9M
+8.9%
246.1M
+21.0%
203.3M
+29.7%
156.7M
Cost of Revenue
3.3M
+21.3%
2.7M
-8.2%
3.0M
-62.5%
8.0M
+240.3%
2.3M
Gross Profit
239.4M
-9.7%
265.2M
+9.1%
243.1M
+24.4%
195.4M
+26.6%
154.4M
Operating Expenses
370.1M
+0.7%
367.5M
+1.9%
360.5M
-12.0%
409.8M
+30.3%
314.6M
R&D
215.9M
-0.6%
217.1M
+3.3%
210.2M
-24.8%
279.6M
+28.4%
217.8M
SG&A
154.2M
+2.5%
150.4M
+0.0%
150.4M
+15.5%
130.2M
+34.5%
96.8M
Operating Income
-130701000
-27.8%
-102293000
+12.9%
-117424000
+45.2%
-214459000
-33.9%
-160182000
EBITDA
-126367000
-28.7%
-98160000
+13.5%
-113462000
+46.7%
-213001000
-35.4%
-157306000
Net Income
-109971000
+4.1%
-114646000
-23.9%
-92528000
+59.7%
-229394000
-78.4%
-128606000
EPS (Basic)
$-0.66
+4.3%
$-0.69
-23.2%
$-0.56
+60.3%
$-1.41
-76.2%
$-0.80
EPS (Diluted)
$-0.66
+4.3%
$-0.69
-23.2%
$-0.56
+66.1%
$-1.65
-106.2%
$-0.80
Shares (Diluted)
166.2M
+0.5%
165.4M
+0.3%
164.9M
+18.4%
139.2M
-12.9%
159.8M
Ionis Pharmaceuticals (IONS) — Financials